Tumor Vaccines for Malignant Gliomas

Visish M. Srinivasan, Sherise D. Ferguson*, Sungho Lee, Shiao Pei Weathers, Brittany C.Parker Kerrigan, Amy B. Heimberger

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


Despite continued research efforts, glioblastoma multiforme (GBM) remains the deadliest brain tumor. Immunotherapy offers a novel way to treat this disease, the genetic signature of which is not completely elucidated. Additionally, these tumors are known to induce immunosuppression in the surrounding tumor microenvironment via an array of mechanisms, making effective treatment all the more difficult. The immunotherapeutic strategy of using tumor vaccines offers a way to harness the activity of the host immune system to potentially control tumor progression. GBM vaccines can react to a variety of tumor-specific antigens, which can be harvested from the patient’s unique pathological condition using selected immunotherapy techniques. This article reviews the rationale behind and development of GBM vaccines, the relevant clinical trials, and the challenges involved in this treatment strategy.

Original languageEnglish (US)
Pages (from-to)345-357
Number of pages13
Issue number2
StatePublished - Apr 1 2017
Externally publishedYes


  • Dendritic cells
  • Glioblastoma
  • Glioma
  • Rindopepimut
  • Tumor vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Tumor Vaccines for Malignant Gliomas'. Together they form a unique fingerprint.

Cite this